-
Adolescent Health, Medicine and Therapeutics
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Emerging treatment options in bipolar disorderin adolescents: focus on ziprasidone
Review
(2550) Views (658) Full article downloads
Authors: Afshan A Khan, Jeffrey R Strawn, Paul E Croarkin
Published Date October 2010
Volume 2010:1 Pages 137 - 143
DOI: http://dx.doi.org/10.2147/AHMT.S7586
Afshan A Khan1, Jeffrey R Strawn2, Paul E Croarkin11Department of Psychiatry, UT Southwestern Medical Center Dallas, TX, USA; 2Department of Psychiatry, University of Cincinnati, Cincinnati, OH, USA
Abstract: Bipolar disorder is a debilitating, and chronic condition in adolescents. The rate of diagnosis and treatment is increasing in adolescents despite considerable controversy regarding criteria for diagnosis. Atypical antipsychotics have been studied extensively for adult and adolescent bipolar disorder. Ziprasidone is an atypical neuroleptic with novel receptor-binding activity and a favorable side effect profile. It has been marketed in the US since 2000, and now has several indications approved by the US Food and Drug Administration. Emerging case reports, open-label studies, and randomized controlled trials suggest that it may have a role in the management of adolescent bipolar disorder. Somnolence, akathisia, tachycardia, and prolonged corrected QT intervals are major safety concerns. There are no definitive guidelines for dosing ziprasidone in adolescents based on current literature. However, optimal treatment may involve dosages near the adult range. Given minimal data and understanding of its effects on cardiac conduction, it might be prudent to obtain electrocardiograms prior to initiation and during treatment. While not a first-line medication choice for adolescents struggling with bipolar disorder, it may be considered in certain situations in which metabolic side effects and weight gain are of concern.
Keywords: ziprasidone, bipolar disorder, atypical antipsychotics, mood stabilizer, mania, hypomania
Readers of this article also read:
Achieving adolescent adherence to treatment of major depression
Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
Screening and managing depression in adolescents
Emerging role of aripiprazole for treatment of irritability associated with autistic disorder in children and adolescents
Asthma control in adolescents: role of leukotriene inhibitors
Influencing behavioral change by customer engagement amongst youth
Social capital and risk and protective behaviors: a global health perspective
Anxiety in adolescents: Update on its diagnosis and treatment for primary care providers
Developmental trajectories of overweight and obesity of US youth through the life course of adolescence to young adulthood
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




